PMID- 26999331
OWN - NLM
STAT- MEDLINE
DCOM- 20170620
LR  - 20211204
IS  - 1208-6002 (Electronic)
IS  - 0829-8211 (Linking)
VI  - 94
IP  - 3
DP  - 2016 Jun
TI  - Inhibition of mTOR enhances radiosensitivity of lung cancer cells and protects 
      normal lung cells against radiation.
PG  - 213-20
LID - 10.1139/bcb-2015-0139 [doi]
AB  - Radiotherapy has been used for a long time as a standard therapy for cancer; 
      however, there have been no recent research breakthroughs. Radioresistance and 
      various side-effects lead to the unexpected outcomes of radiation therapy. 
      Specific and accurate targeting as well as reduction of radioresistance have been 
      major challenges for irradiation therapy. Recent studies have shown that 
      rapamycin shows promise for inhibiting tumorigenesis by suppressing mammalian 
      target of rapamycin (mTOR). We found that the combination of rapamycin with 
      irradiation significantly diminished cell viability and colony formation, and 
      increased cell apoptosis, as compared with irradiation alone in lung cancer cell 
      line A549, suggesting that rapamycin can enhance the effectiveness of radiation 
      therapy by sensitizing cancer cells to irradiation. Importantly, we observed that 
      the adverse effects of irradiation on a healthy lung cell line (WI-38) were also 
      offset. No enhanced protein expression of mTOR signaling was observed in WI-38 
      cells, which is normally elevated in lung cancer cells. Moreover, DNA damage was 
      significantly less with the combination therapy than with irradiation therapy 
      alone. Our data suggest that the incorporation of rapamycin during radiation 
      therapy could be a potent way to improve the sensitivity and effectiveness of 
      radiation therapy as well as to protect normal cells from being damaged by 
      irradiation.
FAU - Zheng, Hang
AU  - Zheng H
AD  - a School of Pharmaceutical Science and Technology, Tianjin University, Nankai 
      District, Tianjin 300072, China.
FAU - Wang, Miao
AU  - Wang M
AD  - a School of Pharmaceutical Science and Technology, Tianjin University, Nankai 
      District, Tianjin 300072, China.
AD  - b National Engineering Research Center of Microbial Medicine, New Drug Research 
      and Development Centre of North China Pharmaceutical Group Corporation, Hebei, 
      Shijiazhuang 050015, China.
FAU - Wu, Jing
AU  - Wu J
AD  - a School of Pharmaceutical Science and Technology, Tianjin University, Nankai 
      District, Tianjin 300072, China.
FAU - Wang, Zhi-Ming
AU  - Wang ZM
AD  - b National Engineering Research Center of Microbial Medicine, New Drug Research 
      and Development Centre of North China Pharmaceutical Group Corporation, Hebei, 
      Shijiazhuang 050015, China.
FAU - Nan, Hai-Jun
AU  - Nan HJ
AD  - c School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, 
      Guangzhou 510006, China.
FAU - Sun, He
AU  - Sun H
AD  - a School of Pharmaceutical Science and Technology, Tianjin University, Nankai 
      District, Tianjin 300072, China.
LA  - eng
PT  - Journal Article
DEP - 20160118
PL  - Canada
TA  - Biochem Cell Biol
JT  - Biochemistry and cell biology = Biochimie et biologie cellulaire
JID - 8606068
RN  - 0 (H2AX protein, human)
RN  - 0 (Histones)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Apoptosis/drug effects/radiation effects
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Comet Assay
MH  - DNA Damage/drug effects/genetics/radiation effects
MH  - Gamma Rays
MH  - Histones/metabolism
MH  - Humans
MH  - Lung/cytology/*radiation effects
MH  - Lung Neoplasms/*drug therapy/genetics/*radiotherapy
MH  - Radiation-Sensitizing Agents/*pharmacology
MH  - Ribosomal Protein S6 Kinases, 70-kDa/metabolism
MH  - Sirolimus/*pharmacology
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
OTO - NOTNLM
OT  - cancer pulmonaire
OT  - lung cancer
OT  - mTOR (<< mammalian target of rapamycin >>)
OT  - mammalian target of rapamycin (mTOR)
OT  - radiation
OT  - radiosensibilite
OT  - radiosensitivity
OT  - rapamycin
OT  - rapamycine
EDAT- 2016/03/22 06:00
MHDA- 2017/06/21 06:00
CRDT- 2016/03/22 06:00
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2017/06/21 06:00 [medline]
AID - 10.1139/bcb-2015-0139 [doi]
PST - ppublish
SO  - Biochem Cell Biol. 2016 Jun;94(3):213-20. doi: 10.1139/bcb-2015-0139. Epub 2016 
      Jan 18.